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Highly active antiretroviral therapy (HAART) sup-
presses HIV-1 replication but cannot eliminate the
virus because HIV-1 establishes latent infection.
Interruption of HAART leads to a rapid rebound of
viremia, so life-long treatment is required. Efforts to
purge the latent reservoir have focused on reactivat-
ing latent proviruses without inducing global T cell
activation. However, the killing of the infected cells
after virus reactivation, which is essential for elimina-
tion of the reservoir, has not been assessed. Here we
show that after reversal of latency in an in vitro
model, infected resting CD4+ T cells survived despite
viral cytopathic effects, even in the presence of autol-
ogous cytolytic T lymphocytes (CTLs) from most
patients on HAART. Antigen-specific stimulation of
patient CTLs led to efficient killing of infected cells.
These results demonstrate that stimulating HIV-1-
specific CTLs prior to reactivating latent HIV-1 may
be essential for successful eradication efforts and
should be considered in future clinical trials.
INTRODUCTION
The extremely stable latent reservoir for HIV-1 in resting memory
CD4+ T cells (Chun et al., 1995, 1997a, 1997b; Finzi et al., 1997;
Wong et al., 1997) is amajor barrier to viral eradication. In latently
infected cells, the integrated provirus is transcriptionally silent
(Hermankova et al., 2003; Chun et al., 2003) but is able to
produce replication-competent virus after cellular activation
(Finzi et al., 1997;Wong et al., 1997; Chun et al., 1997b). Because
of the stability of the reservoir (Siliciano et al., 2003; Strain
et al., 2003), life-long antiretroviral therapy is required, raising
concerns about adverse effects over decades of therapy, the
evolution of resistance, and the financial burden of treatment.
Strategies to eradicate HIV-1 from infected individuals are there-
fore urgently needed.Efforts to eradicate HIV-1 have focused on reactivating latent
proviruses. Early studies with IL-2 or IL-2 plus CD3 antibodies to
reactivate latent HIV-1 failed to eliminate the reservoir and
caused significant toxicity as a result of global T cell activation
(Chun et al., 1999; Prins et al., 1999; van Praag et al., 2001; Stell-
brink et al., 2002; Kulkosky et al., 2002). More recent studies
have focused on identifying small molecules that reactivate
latent virus without inducing host cell activation (Richman
et al., 2009). Three FDA-approved drugs, valproic acid (Ylisasti-
gui et al., 2004), suberoylanilide hydroxamic acid (SAHA)
(Contreras et al., 2009; Archin et al., 2009; Edelstein et al.,
2009), and disulfiram (Xing et al., 2011), can reactivate latent
virus in primary cell models and/or cells from infected individ-
uals. Clinical studies of valproic acid, which has histone deace-
tylase (HDAC) inhibitor activity, have not shown a consistent
decrease in the latent reservoir (Lehrman et al., 2005; Steel
et al., 2006; Siliciano et al., 2007; Archin et al., 2008, 2010;
Sagot-Lerolle et al., 2008). These studies raise a critical issue:
the fate of this reservoir after virus reactivation in resting CD4+
T cells. It is generally presumed that infected cells will die after
reactivation of virus gene expression either as a result of viral
cytopathic effects (CPEs) or host immune responses or both.
Because newer approaches for reactivating latent HIV-1 utilize
agents that do not induce global T cell activation, it is important
to determine whether viral CPE or host responses can eliminate
latently infected resting CD4+ T cells after virus reactivation.
Direct killing of infected cells by HIV-1 through caspase-
dependent or -independent mechanisms has been observed in
activated CD4+ T cells (Roshal et al., 2001; Bolton et al., 2002;
Sakai et al., 2006; Shedlock et al., 2008). Other studies showed
that early events in abortive HIV-1 infection induced cell death in
resting CD4+ T cells (Zhou et al., 2008; Doitsh et al., 2010).
However, whether the reversal of viral latency causes cell death
in resting CD4+ T cells or not has not been assessed. Besides
viral CPE, host immunity is also presumed to eliminate the
latently infected CD4+ T cells after virus reactivation. Cytolytic
T lymphocytes (CTLs) are a major component of the host
response to HIV-1. CTLs partially limit viral replication (Walker
et al., 1987; Koup et al., 1994; Borrow et al., 1997; Schmitz
et al., 1999; Gandhi and Walker, 2002; Hersperger et al., 2011)Immunity 36, 491–501, March 23, 2012 ª2012 Elsevier Inc. 491
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Figure 1. Effect of SAHA on the Frequency of Latently Infected Cells
PBMCs from patients on HAART were isolated and cultured in basal medium
with or without 500 nM SAHA for 6 days. Efavirenz, raltegravir, and enfuvirtide
were added in the culture to prevent further rounds of viral replication. Resting
CD4+ T cells were then isolated from the cultures. The frequency of cells
harboring replication-competent HIV-1 was then measured by a previously
described coculture assay (Siliciano and Siliciano, 2005). See also Figure S1.
Immunity
CTL-Mediated Elimination of HIV-1 Latent Reservoirbut show functional defects in patients with progressive disease
that are not restored with HAART (Kalams et al., 1999; Sa´ez-
Cirio´n et al., 2007; Migueles et al., 2008, 2009; Hersperger
et al., 2010). It is unknown whether CTLs can kill resting CD4+
T cells in which latent infection has been reversed. In this study,
we generated latently infected cells from primary CD4+ T cells as
previously reported (Yang et al., 2009). SAHA was used to
reactivate latent HIV-1 in resting CD4+ T cells. We found that
virus reactivation did not cause death of infected cells. CTLs
from patients on HAART failed to kill autologous latently infected
CD4+ T cells after latent viruses were reactivated. Antigen-
specific stimulation of patient CTLs prior to virus reactivation
led to rapid and effective killing of infected cells. Our results
suggest that reactivation of latent HIV-1 will not purge the viral
latent reservoir. Stimulation of HIV-1-specific CTL responses
prior to virus reactivation may be essential for the viral
eradication.
RESULTS
Reactivation of Latent HIV-1 In Vitro without T Cell
Activation Does Not Affect the Latent Reservoir
We first examined the stability of HIV-1 latent reservoir in resting
CD4+ T cells after treatment with agents that reactivate latent
HIV-1 without causing T cell activation. If viral CPE or CTL
responses cause the death of infected resting CD4+ T cells, reac-
tivating latent HIV-1 should result in reduction or elimination of
latent reservoir. We used the histone deacetylase inhibitor
SAHA, an FDA-approved drug used to treat cutaneous T cell
lymphoma. SAHA has been shown to reactivate latent HIV-1 in
peripheral blood mononuclear cells (PBMCs) from HIV-1-
infected individuals on HAART (Contreras et al., 2009; Archin
et al., 2009). We treated PBMCs from patients on HAART with
SAHA for 6 days. After treatment with SAHA, the frequency of
latently infected resting CD4+ T cells was measured by the stan-
dard limiting dilution virus culture assay (Figure 1). Infected cells
were detected in 9/9 samples at frequencies similar to those in
parallel cultures set up without SAHA. These results indicate492 Immunity 36, 491–501, March 23, 2012 ª2012 Elsevier Inc.that reversal of latent infection alone is not sufficient to eliminate
the latent reservoir in resting CD4+ T cells.
Viral CPEs Do Not Cause the Death of Infected Resting
CD4+ T Cells
To provide further evidence that viral CPE do not cause the death
of infected resting CD4+ T cells, we used freshly isolated primary
resting CD4+ T cells to assess cell killing after infection. Resting
cells were infected with a replication-competent HIV-1 (NL4-3-
Dnef-EGFP) with all open reading frames (ORFs) intact except
nef, which was disrupted by EGFP (Figure S1 available online).
Although abortive infection with incomplete reverse transcription
can cause cell death in resting CD4+ T cells (Doitsh et al., 2010),
steps in the life cycle through integration are already complete in
latently infected cells. Therefore, we focused on the fate of
productively infected (GFP+) cells. Productively infected resting
CD4+ T cells survived after acute infection whereas productively
infected cells that were in an activated state rapidly died (Figures
2A and 2B). In the activated CD4+ T cell population, infected cells
with higher viral gene expression died faster because the mean
fluorescent intensity of GFP+ cells decreased by half from day
3 to day 4 after infection (Figure 2C). The survival of resting
CD4+ T cells may reflect 20-fold lower viral gene expression
than in activated cells.
We also evaluated the effects of reversing latency in a previ-
ously described primary cell model (Yang et al., 2009). Latently
infected CD4+ T cells were generated in vitro by using a replica-
tion-deficient HIV-1 reporter virus NL4-3-Dnef-Dpol-EGFP (Fig-
ure S1). This vector expresses Vif, Vpr, and Env, the HIV-1
gene products most commonly associated with CPE, and all
other viral genes except pol and nef. The latter is disrupted by
the insertion of the GFP coding sequence. Viral latency was then
reversed with CD3 plus CD28 antibodies or SAHA, and cultures
were monitored for GFP expression and markers of cell death
(Annexin V staining). SAHA at 500 nM is not toxic to resting
CD4+ or CD8+ T cells and does not activate T cells (Figure S2).
With anti-CD3 plus anti-CD28 costimulation, a substantial frac-
tion of GFP+ infected cells died rapidly (Figure 2D), confirming
that viral CPE can be observed in this system despite transduc-
tion with Bcl-2. However, when latency was reversed without
T cell activation via SAHA, GFP+ infected cells survived through-
out the 18 day observation period (Figures 2D and 2E). To rule
out the possibility that the stable GFP+ fraction in the SAHA-
treated group was due to continuous reactivation of latently in-
fected CD4+ T cells, GFP+ fractions were purified by cell sorting
from SAHA-treated and costimulated cultures for further anal-
ysis. No cell death was observed in purified infected resting
CD4+ T cells after reversal of viral latency by SAHA. In contrast,
cells treated with CD3 plus CD28 antibodies became activated
and died rapidly (Figure 2F). Thus, under conditions where viral
CPEs kill activated CD4+ T cells, resting CD4+ T cells survive,
indicating that immune clearance may be critical for eradication
strategies that reverse latency without T cell activation.
CD8+ T Cells from Patients on HAART Do Not Kill
Infected CD4+ T Cells after Virus Reactivation
The cytolytic capacity of CD8+ T cells in patients with progres-
sive disease is defective and is not restored with HAART (Kalams
et al., 1999; Sa´ez-Cirio´n et al., 2007; Migueles et al., 2008, 2009;
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Figure 2. Resting CD4+ T Cells Are Not
Killed by Viral CPE
(A–C) Resting CD4+ T cells are not killed by viral
CPE after acute infection. Primary resting CD4+
T cells were isolated and treated with 500 nM
SAHA or CD3 and CD28 antibodies for 1 day and
then infected with NL4-3-Dnef-EGFP. Infected
cells were either activated with CD3 plus CD28
antibodies or left in a resting state. Efavirenz and
enfuvirtide were added to block additional rounds
of viral replication at day 3. GFP expression and
annexin-V staining were analyzed by FACS.
(D–F) Resting CD4+ T cells latently infected with
HIV-1 are not killed by viral CPE after virus re-
activation. Bcl-2-transduced CD4+ T cells were
infected with NL4-3-Dnef-Dpol-EGFP to generate
latent infection in vitro. To reactivate latent HIV-1,
cells were treated with 500 nM SAHA or CD3 and
CD28 antibodies. In (D) and (E), the fraction of
remaining GFP+ cells and the fraction of annexin-
V-positive cells were monitored by FACS analysis.
In (F), GFP+ cells were purified by sorting and
cultured for additional 7 days. Cell viability was
monitored by forward and side scatter.
Numbers in the quadrant indicate the percentage
of cells. Error bars represent SEM, n = 3. See also
Figure S2.
Immunity
CTL-Mediated Elimination of HIV-1 Latent ReservoirHersperger et al., 2010). It is unknown whether CTLs from these
patients can kill resting CD4+ T cells in which latent infection has
been reversed. We therefore developed a coculture system to
evaluate CTL-mediated killing of autologous latently infected
CD4+ T cells. HIV-1 latently infected cells were generated from
primary CD4+ T cells from HIV-1-infected and uninfected donors
as described previously (Yang et al., 2009) with the replication-
deficient HIV-1 reporter virus NL4-3-Dvpr-Denv-drEGFP. In this
reporter virus, genes important for CTL recognition such as
gag are intact, but vpr is inactivated to improve the yield of
latently infected cells (Figure S1). Latently infected cells were
then treated with SAHA for 2 days and cocultured with freshly
isolated autologous CD8+ T cells at a 1:1 ratio to determine
whether they could be killed after the reversal of latency. In this
primary cell model, SAHA reactivates latent HIV-1 to the same
extent that costimulation with CD3 and CD28 antibodies does,
although with slower kinetics (Figure 3A). Latently infected cells
became GFP positive after SAHA treatment and expressed
HIV-1 proteins such as Gag, an important target antigen for
HIV-1-specific CTLs (Figure 3B).
In the representative experiment shown in Figure 3C, latently
infected cells were generated by superinfection of primary
CD4+ T cells from an elite controller (EC32), a patient whoImmunity 36, 491–50controls HIV-1 without treatment (Deeks
and Walker, 2007; O’Connell et al.,
2009). Such patients generally have high
HIV-1-specific CTL activity (Sa´ez-Cirio´n
et al., 2007; Migueles et al., 2008, 2009;
Hersperger et al., 2010). SAHA induced
reactivation of latent HIV-1, with 1.22%
of the cells becoming GFP+ after 2 days.
In the absence of CD8+ T cells, the frac-tion of GPF+ cells increased slightly over the next 8 days.
However, when autologous CD8+ T cells were present, the
number of GFP+ cells decreased dramatically. When latently
infected cells were generated from HIV-negative donors, the
fraction of CD4+ T cells expressing GFP did not decrease during
the coculture with autologous CD8+ T cells, which lack HIV-1-
specific CTL activity (Figure 3D). Three HLA-B57+ ECs with
HIV-1-specific CTL activity were also included as positive
controls. A substantial decrease in GFP+ cells was observed
for all three (Figure 3D). This decrease is not due to nonspecific
killing by CD8+ T cells or spontaneous reentry into latency
because no decrease was observed in cultures from HIV-nega-
tive donors. Rather, the decrease is likely to reflect HIV-1-
specific killing by CD8+ T cells (see below).
We also used disulfiram to reactivate latent virus in CD4+
T cells and monitored cell death with the presence of autologous
CD8+ T cells. A modest killing effect was observed at day 2 in
cultures from two HLA-B57+ ECs (Figure S3A). No additional kill-
ing effectwasobserved after longer periods of culture in thepres-
ence of disulfiram, probably because of the general cytotoxicity
of disulfiram. Therefore, disulfiramwas not used for further study.
In the case of all three ECs, a notable fraction of GFP-positive
cells (20% to 40%) remained after 8 days of coculture. To test1, March 23, 2012 ª2012 Elsevier Inc. 493
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Figure 3. Autologous CD8+ T Cells from
Patients on HAART Do Not Kill Infected
CD4+ T Cells after Virus Reactivation
(A) 500 nM SAHA reactivates latent viruses. The
effect of SAHA was normalized to effect of cos-
timulation with CD3 and CD28 antibodies at day 2.
(B) GFP expression is correlated with Gag protein
expression.
(C) Calculation of residual CD4+GFP+ cells. In vitro
latently infected CD4+ T cells generated from Elite
controller 32 were treated with SAHA and cocul-
tured with freshly isolated autologous CD8+ T cells
at a 1:1 ratio. Numbers in the quadrant indicate the
percentage of cells.
(D) Effect of CD8+ T cells from different healthy
donors, ECs, and patients on HAART on the
survival of autologous CD4+ T cells in which latent
HIV-1 infection has been reversed. E:T ratio is 1:1.
(E) Killing of latently infected cells is observed with
higher E:T ratio. Freshly isolated autologous CD8+
T cells were cocultured with SAHA-treated CD4+
T cells at different E:T ratio.
Error bars represent SEM, n = 3. See also
Figure S3.
Immunity
CTL-Mediated Elimination of HIV-1 Latent Reservoirwhether these cells were resistant to CTL-mediated killing, we
added freshly isolated autologous CD8+ T cells for the second
time at day 8 of coculture and continued the culture for an addi-
tional 8 days. A further reduction of GFP-positive cells was
observed (Figure S3B). Therefore, the residual GFP-positive cells
were not resistant to CTL-mediated killing. Amore likely explana-
tion is that the viability of CD8+ T cells decreased after several
days of culture in vitro whereas CD4+ T cells survived better as
a result of Bcl-2 overexpression.
Eradication strategies will be implemented in patients with
progressive disease who respond to HAART. Thus it is important
to determine whether such patients have CTLs that kill infected
cells after reversal of latency. Of cultures from eight patients
on HAART, only one had CD8+ T cells that eliminated
latently infected CD4+ T cells at a 1:1 effector-to-target (E:T) ratio494 Immunity 36, 491–501, March 23, 2012 ª2012 Elsevier Inc.(Figure 3D). Despite the presence of
autologous CD8+ T cells, latently infected
cells from the other seven patients
survived with a median half-life of
34.2 days, compared with 4.3 days in
the case of EC (Figure S4). These results
suggested that reactivating latent HIV-1
in patients on HAART might not lead to
the elimination of this reservoir because
of the weak CTL responses in these
patients.
CTL Responses Increase at Higher
E:T Ratios
The failure of CD8+ T cells from patients
on HAART to clear latently infected cells
after virus reactivation could be due
to an insufficient number of HIV-1-
specific CD8+ T cells or diminished CTL
function (Migueles et al., 2008, 2009).Even at higher E:T ratios, no substantial killing of GFP+ cells
was observed in cultures from patients on HAART at day 2 of
coculture (Figure 3E). Killing of GFP+ cells was observed only
at high E:T ratios after a longer period of coculture (Figure 3E).
These results suggest limitations in the number and/or cytolytic
capacity of HIV-1-specific CTLs that can be restored after cocul-
ture with infected target cells. We therefore hypothesized that
prior antigen-specific stimulation of CD8+ T cells might facilitate
the elimination of latently infected cells after virus reactivation.
Prestimulation of Patient CD8+ T Cells Leads
to Elimination of HIV-1 Latently Infected Cells
CD8+ T cells from infected donors were stimulated with HIV-1
Gag peptides and IL-2 for 6 days and then cocultured with autol-
ogous CD4+ T cells treated with SAHA as described above. We
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Figure 4. Prestimulation of CD8+ T Cells Enhanced
CTL Responses
Before coculture, CD8+ T cells from ECs or patients on
HAART were stimulated with B57-restricted Gag peptides
KF11 and TW10 (A) or mixture of 129 Gag peptides
(B), respectively. Solid lines, unstimulated CD8+ T cells;
dashed lines, prestimulated CD8+ T cells. Error bars
represent SEM, n = 3. See also Figure S4.
Immunity
CTL-Mediated Elimination of HIV-1 Latent Reservoirused B57-restricted Gag peptides to stimulate CD8+ T cells from
HLA B57+ EC and a mixture of 129 Group M consensus Gag
peptides to stimulate CD8+ T cells from patients on HAART.
For ECs, who generally have strong CTL responses, prestimula-
tion led to more rapid and effective CTL clearance of cells reac-
tivated from latency (Figure 4A). For patients on HAART, signifi-
cant killing was observed at a 1:1 E:T ratio even for patients from
whom almost no CTL activity was observed without prestimula-
tion (Figure 4B). The median half-life of latently infected CD4+
T cells from those patients was reduced from 34.2 days to
3.6 days (Figure S4). Increasing the E:T ratio further enhanced
killing (Figure 4B). Prestimulation with Gag peptides and IL-2
caused modest proliferation of HIV-1-specific CTLs, but IL-2
alone did not (Figures 5A and 5B). Prestimulation also upregu-
lated granzyme B, INF-g, CD107a, and perforin production, but
not IL-2 production, in HIV-1-specific CTLs (Figure 5C). TheseImmunity 36, 4results suggest that antigen-specific stimulation
restored killing ability of CD8+ T cells from
patients on HAART and therefore facilitated
the elimination of infected resting CD4+ T cells
after reversal of viral latency.
Reduction in GFP+ Cells in Coculture
Is Caused by Direct Killing
by HIV-1-Specific CTLs
CTL killing requires cell-to-cell contact and is
MHC class I restricted. As shown in Figure 6A,
the clearance of GFP+ cells was abolished
when CD4+ and CD8+ T cells were cocultured
in trans-well plates, which allow the exchange
of cytokines but block cell-to-cell contact. The
reduction in GFP+ cells was inhibited by the
MHC class I-specific antibody W6/32, which
blocks T cell recognition of class I MHC-peptide
complexes (Figure 6A). W6/32 did not induce re-
activation or affect activation by SAHA (Fig-
ure S5). To confirm that the observed killing
required expression of viral genes,we generated
latently infected cells with the virus NL4-3-D6-
drEGFP, which expresses only Tat and Rev (Fig-
ure S1). As shown in Figure 6B, there was no
CTL-induced reduction in GFP+ cells in the
NL4-3-D6-drEGFPgroup in two of three patients
and only a partial reduction in the third. This
reduction was probably due to Rev-specific
CTLs (data not shown). In control cultures from
the same patients, there was robust killing of
cells infected with NL4-3-Dvpr-Denv-drEGFP,
which expresses all viral genes except vpr andenv. Thus, these CTL responses specifically target viral proteins.
For unstimulated CD8+ T cells from patients on HAART, Gag
protein is the major target antigen (Figures 6B and 6C). It re-
mained possible that the disappearance of GFP+ cells was due
to CTL-mediated inhibition of viral gene transcription or transla-
tion. Therefore,we isolated theCD4+Tcells after 8dayscoculture
andactivated themwithCD3andCD28antibodies.NoGFP+cells
were rescued (Figure 6D), indicating that the target cells had
been killed. These observations confirmed that the disappear-
ance of GFP+ cells in coculture was due to CTL-mediated killing,
which was contact dependent and MHC class I restricted.
Prestimulated Patient CD8+ T Cells Eliminate
CD4+ T Cells Infected with Autologous Viruses
It is important to investigate whether CD8+ T cells stimulated
with Group M consensus Gag peptides can recognize viruses91–501, March 23, 2012 ª2012 Elsevier Inc. 495
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Figure 5. Prestimulation with Gag Peptides plus IL-2 Induces Proliferation of HIV-1-Specific CD8+ T Cells
(A and B) Proliferative responses. PBMCs from patients on HAART were stained with CFSE and cultured with indicated treatments for 6 days. CD8+ T cells were
then isolated and analyzed with FACS. Numbers in the quadrant indicate the percentage of cells.
(C) Production of granzyme B, interferon-g, perforin, CD107a, and IL-2. PBMCs from two patients were stained with CFSE and cultured with indicated treatments
for 6 days. CD8+ T cells were then isolated from PBMCs and used for intracellular staining for the indicated proteins.
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CTL-Mediated Elimination of HIV-1 Latent Reservoircoming from the same patient’s latent reservoir. CD4+ T cells iso-
lated from patients on HAART were infected with viruses recov-
ered from resting CD4+ T cells from the same patient and then
cocultured with autologous CD8+ T cells. The viruses recovered
from patient resting CD4+ T cells were probably a mixture of
different viral clones. In Figures 7A and 7B, most of the infected
CD4+ T cells were killed 3 days after coculture with stimulated
autologous CTLs. This killing was contact dependent as shown
by the fact that no killing was observed when CD4+ T cells
and CD8+ T cells were cultured in transwells. Because the killing
efficiency was similar for target cells infected with patient-
derived virus and HIV-1 BaL (Figure 7C), the small fraction of496 Immunity 36, 491–501, March 23, 2012 ª2012 Elsevier Inc.infected cells that are not killed are probably not due to the resis-
tance to CTL killing. It is more probably due to the insufficient
time for CTL killing, which was limited to 3 days because of the
viability of infected primary CD4+ T cells cultured in vitro. These
results demonstrate that stimulated patient CTLs efficiently killed
the target cells infected with the autologous viruses.
DISCUSSION
Purging the latent reservoir for HIV-1 requires reactivation of
latent virus and then elimination of infected host cells. Recent
studies have identified several pharmacologic agents that
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Figure 6. Reduction in GFP+ Cells in Coculture Is Caused by Direct Killing by HIV-1-Specific CTLs
(A) Reduction of GFP+ cells is cell contact dependent andMHC class I restricted. Prestimulated autologous CD8+ T cells from patients on HAARTwere cocultured
with SAHA-treated CD4+ T cells at a 4:1 ratio with 500 nM SAHA and the indicated treatment for 4 days.
(B and C) Elimination of latently infected cells requires viral gene expression. Latently infected cells were generated with indicated viruses. Unstimulated
autologous CD8+ T cells were cocultured with SAHA-treated latently infected CD4+ T cells at a 4:1 ratio with 500 nM SAHA for 4 days.
(D) GFP+ cells cannot be recovered after coculture. CD4+ T cells were isolated after 8 days of coculture with prestimulated autologous CD8+ T cells at a 4:1 ratio in
the presence of 500 nM SAHA, and then costimulated with CD3 and CD28 antibodies for 2 days. GFP+ cells were analyzed with FACS and normalized to the
control culture set up without CD8+ T cells.
Error bars represent SEM, n = 3. See also Figure S6.
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CTL-Mediated Elimination of HIV-1 Latent Reservoirreverse latency without inducting global T cell activation (Ylisas-
tigui et al., 2004; Contreras et al., 2009; Archin et al., 2009; Yang
et al., 2009; Xing et al., 2011). In our study, SAHA was tested for
the reactivation of latent virus and was shown to be as effective
as general T cell activators in our primary cell model, although
with slower kinetics. SAHA is currently used in the treatment of
cutaneous T cell lymphoma but is associated with common
gastrointestinal and hematologic adverse effects. After the
development of several human primary cell models of HIV-1
latency (Sahu et al., 2006; Marini et al., 2008; Bosque and
Planelles, 2009; Yang et al., 2009; Tyagi et al., 2010), other
agents that reactivate latent virus have been identified (Yang
et al., 2009; Xing et al., 2011), and it is likely that many additional
agents will be found in these screens. Mechanisms of HIV-1
latency are also being extensively studied in these primary cell
models and cell line models (Jordan et al., 2003). Eventually,
combination of agents affecting different pathways will probably
be used to maximally reactivate latent viruses in vivo. However,
the reactivation of latent virus is only the first step to viral eradi-
cation. Elimination of the infected cells after virus reactivation
has not been previously studied.It is often assumed that the latently infected CD4+ T cells will
die after the virus is reactivated because of viral CPE or host
immunity or both. Here we demonstrate that neither viral CPEs
nor CD8+ T cells from patients on HAART are sufficient to
cause immediate death of latently infected resting CD4+ T cells
after virus reactivation with agents that do not cause T cell
activation. In our in vitro model of HIV-1 latency, Bcl-2 is overex-
pressed in order to promote long-term survival of primary CD4+
T cells. Bcl-2 overexpression in our system imposes some
limitations and could potentially interfere with the study of viral
CPE or the CTL response. To address this concern, freshly iso-
lated primary resting CD4+ T cells were also used for the study
of viral CPEs and similar effects were observed. Specifically,
we showed that reactivation of latent HIV-1 in freshly isolated,
untransduced resting CD4+ T cells from patients on HAART
does not result in death to the infected cells. With regard to
studies of CTL-mediated killing of infected cells, we showed
that overexpression of Bcl-2 does not protect infected target
cells from cytolytic effects of CD8+ T cells, which was consistent
with other studies (Zhang et al., 2001; Packard et al., 2007;
Goping et al., 2008). Therefore, the lack of cell death after virusImmunity 36, 491–501, March 23, 2012 ª2012 Elsevier Inc. 497
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Figure 7. Prestimulated CD8+ T Cells from Patients
on HAART Eliminate CD4+ T Cells Infected with
Autologous Viruses
(A and B) PBMCs from patients on HAART were isolated
and cultured in basal medium for 5–6 days to allow the
decay of remaining intracellular triphosphorylated nucle-
oside/nucleotide reverse transcriptase inhibitors, and then
stimulated with phytohemagglutinin. CD4+ T cells were
isolated 2 days after stimulation and infected with autol-
ogous viruses. Prestimulated autologous CD8+ T cells
were added into the culture 4 hr after infection at the
effector-to-target ratio 1:1. Raltegravir and enfuvirtide
were added in the culture 2 days after infection to prevent
further rounds of viral replication. The fraction of residual
Gag+CD4+ T cells was measured after 3 days of coculture
and normalized to the control culture without CTL.
Numbers in the quadrant indicate the percentage of cells.
(C) Patient autologous viruses or HIV-1 BaL were used to
infected CD4+ T cells. Infected cells were then cocultured
with CD8+ T cells as described above. The fraction of
residual Gag+CD4+ T cells was measured after 3 days
of coculture and normalized to the control culture
without CTL.
Error bars represent SEM, n = 3.
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CTL-Mediated Elimination of HIV-1 Latent Reservoirreactivation in our in vitro model is unlikely to be due to overex-
pression of Bcl-2.
Resting memory CD4+ T cells may be resistant to viral CPE for
several reasons. First, viral gene transcription and translation are
much less efficient in resting cells. Second, resting memory
CD4+ T cells are in general less prone to cell death than activated
CD4+ T cells (Stockinger et al., 2006; Surh et al., 2006; van Leeu-
wen et al., 2009; Taylor and Jenkins, 2011). Third, resting
memory CD4+ T cells remain at a quiescent G0 state after treat-
ment with agents like SAHA, and in this state are less likely to be
affected by the viral proteins Vpr and Vif (Roshal et al., 2001;
Sakai et al., 2006; Shedlock et al., 2008), which cause cell cycle
arrest and cell death in activated cells. Thus, reversing latency
with agents that do not induce global T cell activation will not
eliminate the latent reservoir. Finding a way to eliminate the
cellular reservoir after virus reactivation is thus an important
step to viral eradication.
Although HIV-1-specific CTLs are presumed to be capable of
eliminating latently infected cells after the reversal of latency, we
found that freshly isolated CD8+ T cells from patients on HAART
were effective only at high E:T ratios and with a prolonged period
of coculture. Little killing of infected target cells was observed
within the first 2 days of coculture. One explanation is that the
frequency of HIV-1-specific CD8+ T cells in patients on HAART
is diminished as a result of the lack of antigen stimulation. In
addition, the CTL dysfunction seen in patients with progressive
disease is not fully restored on HAART (Kalams et al., 1999;
Sa´ez-Cirio´n et al., 2007; Migueles et al., 2008, 2009; Hersperger
et al., 2010).
CD8+ T cells from one of eight patients (HAART patient 06) on
HAART retained strong ability to kill infected target cells without
in vitro stimulation. We used Gag peptides to stimulate CD8+
T cells from all eight patients on HAART and found that this
patient had more Gag-specific CD8+ T cells and/or better
antigen-driven proliferation than other patients. We also found498 Immunity 36, 491–501, March 23, 2012 ª2012 Elsevier Inc.that this patient had higher Granzyme B and INF-g production
than a representative control patient after in vitro stimulation
with Gag peptides. This patient also had a notable CTL response
against other HIV-1 proteins. It appears that this patient has
a larger number of HIV-1-specific CD8+ T cells and has broader
recognition of viral epitopes. Unfortunately, the majority of the
patients on HAART does not have such strong CTL response
and may not be able to eliminate the latent reservoir after virus
reactivation.
Here we demonstrated that CTL activity could be restored
through in vitro stimulation with Gag peptides for every patient
on HAART studied. This suggests that HIV-1-specific CTL
responses in patients on HAART are defective but can be
restored to effectively eliminate latently infected resting CD4+
T cells after virus reactivation. Boosting CTL responses and
then reactivating latent HIV-1 may be an efficient strategy to
eradicate HIV-1. Stimulation with other viral proteins could
provide a broader CTL response in some of the patients.
Because reactivation strategies will probably be implemented
with the presence of HAART, further rounds of viral replication
are inhibited and de novo CTL escape mutations cannot arise.
The pre-existing CTL escape variants archived in latent reservoir
can be overcome by inducing strong and broad CTL responses
against multiple viral epitopes and are not an obstacle to
elimination.
Other strategies for promoting the death of infected cells have
been proposed. For example, elegant studies have shown that
cells expressing the HIV-1 Env protein could be targeted with
antibody-conjugated bacterial toxins (Brooks et al., 2003). The
application of this approach may be limited because of the
high variability of the Env protein, drug bioavailability, and poten-
tial adverse effects.
In conclusion, resting CD4+ T cells latently infected with HIV-1
will not be efficiently killed by either viral CPE or host CTL
responses after virus reactivation. Our study strongly suggests
Immunity
CTL-Mediated Elimination of HIV-1 Latent Reservoirthat boosting CTL responses through vaccination prior to virus
reactivation may be essential for eradication of HIV-1 infection.
EXPERIMENTAL PROCEDURES
Study Subjects
Peripheral blood for the isolation of primary CD4+ and CD8+ T cells was
obtained from HIV-1-infected donors (Table S1) and healthy adult volunteers.
This study was approved by the Johns Hopkins Institutional Review Board.
Written informed consent was provided by all study participants. For CTL
study with human primary cell models of HIV-1 latency, each patient and
healthy adult was recruited for at least two visits. CD4+ T cells were isolated
in the first visit for Bcl-2 transduction and then HIV-1 reporter virus infection.
CD8+ T cells were isolated in the second visit to coculture with in vitro infected
autologous CD4+ T cells.
Generation of Latently Infected CD4+ T Cells In Vitro
Primary CD4+ T cells from HIV/AIDS patients or healthy donors were isolated
to generate HIV-1 latent infection in vitro as previously described (Yang et al.,
2009). In brief, primary CD4+ T cells were transduced with Bcl-2 to allow long-
term culture. Bcl-2-transduced primary CD4+ T cells return to a quiescent state
but respond normally to T cell-activating stimuli (Yang et al., 2009). Bcl-2-
transduced cells were infected with HIV-1 reporter viruses. The infected cells
were then cultured for several weeks without activating stimuli to allow estab-
lishment of latency in surviving cells. Flow cytometric cell sorting was used to
remove residual GFP+ cells. This approach produces cultures in which 0.5%–
3% of the cells are latently infected, with the remaining cells (>97%) being
uninfected. All HIV-1 reporter viruses used in this study are listed in Figure S1.
HIV-1 reporter viruses NL4-3-Dnef-Dpol-EGFP and NL4-3-Dnef-EGFP were
used for viral CPE study. HIV-1 reporter virus NL4-3-Dvpr-Denv-drEGFP
was used for CTL studies unless otherwise specified.
Coculture of Autologous CD4+ and CD8+ T Cells
After cell sorting, the purified GFP cells including latently infected cells were
treated with 500 nM SAHA for 2 days before coculture. SAHA-treated CD4+
T cells were cocultured with autologous CD8+ T cells in the presence of
500 nM SAHA in 24-well or 48-well plate. The fraction of residual GFP+CD4+
T cells was measured by FACS. For analysis of contact dependence, CD4+
T cells and CD8+ T cells were placed in separate chambers of trans-well plates
(0.4 mm,Costar). For analysis of MHC-I restriction, the class I-specific antibody
W6/32 was added to the coculture medium at 5 mg/ml.
Prestimulation of CD8+ T Cells
PBMCs from B57+ ECs were isolated and cultured in the presence of B57-
restricted peptides KF11 and TW10 (5 mg/ml for each) and IL-2 (100 U/ml).
PBMCs from patients on HAART were isolated and cultured in the presence
of a mixture of 129 Gag peptides (80 ng/ml for each) (NIH AIDS Reagent
Program) and IL-2 (100 U/ml). CD8+ T cells were isolated 6 days after stimula-
tion for coculture with infected CD4+ T cells.
Recovery of Patient Virus from Resting CD4+ T Cells
Resting CD4+ T cells were isolated from patients on HAART. Coculture assay
was performed to recover and amplify replication-competent viruses as previ-
ously described (Siliciano and Siliciano, 2005). The viruses were recovered
from five to ten million resting CD4+ T cells and were probably a mixture of
different viral clones.
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